贝乐福生命科学公司合同研究CRO经营计划书

Copyright©2002BelevoLifeSciencesCorp.AllRightsReserved.(CRO)20028(Clint),MBA·:16049287268:16042329538:[e-mail]:#103-8400AckroydRoadRichmond,BC,CanadaV6X3E8BelevoLifeSciencesCorporation#103-8400AckroydRoadRichmondBCV6X3E8CanadaNotetotheReadersofthisBusinessPlanTheinformationcontainedinthisBusinessPlanisproprietaryandconfidential.AnyreproductionofthisBusinessPlan,inwholeorinpart,withoutthepriorwrittenconsentofBelevoLifeSciencesCorp.(theCompany),isprohibited.TherecipientoftheBusinessPlanshallnotdirectlyorindirectlydiscloseanyoftheinformationcontainedintheBusinessPlantoanythirdparty.TransmittaloftheBusinessPlanbytheCompanydoesnotgrantanyrightstorecipientwhatsoevertodevelop,manufacture,use,ormarketanythingdescribedherein.TheinformationcontainedintheBusinessPlanisbelievedbytheCompanytobereliable.Thereadermustrecognize,however,thatprojectionsabouttheCompany’sfutureperformanceareinherentlysubjecttoahighdegreeofuncertainty,andnowarrantyofsuchprojectionsisexpressedorimpliedhereby.Itistheresponsibilityofanyprospectiveinvestor,jointventurepartner,orlendertoindependentlyevaluatethefeasibilityandriskofenteringintoabusinesscombinationwiththeCompany.ThereaderofthisBusinessPlandocumentagreestokeeptheinformationinthedocumentconfidential,andtouseitsolelytodeterminewhetherthereader’sorganizationhasaninterestinenteringintodiscussionsregardingapossiblebusinesscombinationwiththeCompany.Shouldthereader’sorganizationdeclinetoparticipate,allmaterialspresentedtothereaderregardingtheCompanyshallbepromptlyreturnedtotheCompany.ThisBusinessPlandoesnotconstituteanoffertosellanysecurities.Anysuchsolicitationwillbeundertakenonlyunderappropriatedocumentsandpursuanttoallapplicablesecuritieslaws.AAALACAssociationforAssessmentandAccreditationofLaboratoryAnimalCareInternationalCROContractResearchOrganizationDOHDepartmentofHealth,theUnitedKingdomFDAFoodandDrugAdministration,theUnitedStates,orUSFDAGLPGoodLaboratoryPracticesIATAInternationalAirTransportAssociation(IATA)ICHInternationalCommitteeonHarmonizationINDInvestigationalNewDrugLOILetterofIntentMHWMinistryofHealthcareandWelfare,JapanNDANewDrugApplicationNIHUnitedStatesNationalInstitutesofHealthNIHOPRRUnitedStatesNationalInstitutesofHealthOfficeofProtectionforResearchRisksOECDOrganisationforEconomicCo-operationandDevelopmentOSHAOccupationalSafetyandHealthAdministration,theUnitedStatesR&DResearchandDevelopmentROIReturnonInvestmentSDAStateDrugAdministration,ChinaSOPStandardOperatingProcedureWTOWorldTradeOrganization1120%(Save,Survive,Succeed)2(Clint)MBA,CEO12·,CTO38FDAGLPSOP23GLP4CRO20%20013050045%3/580%6()75%80%50%40%30%i1........................................................................................................................11.1.................................................................................................................11.2.....................................................................................................11.3.............................................................................................21.4.........................................................................................................21.5.................................................................................................................32............................................................................................................32.1.................................................................................................32.2.....................................................................................................33............................................................................................................53.1.........................................................................................................................53.2.....................................................................................53.3.........................................................54................................................................................................................64.1.................................................................................64.2.....................................................84.3.....................................................................................................84.4.....................................................................................95....................................................................................................95.1.................................................................................................................95.2...............................................................................................................106......................................................................................................................117..................................................................................................................128.....................